InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
20%
T+90 mean return
-15.0%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by BUCKMAN PAUL, Director. Insider active across 3 companies, notably NEUROONE MEDICAL TECHNOLOGIES Corp. Cumulatively, 19 reports have been logged. Split: 1 buy · 0 sell. Total volume traded: €47k. Activity tracked since 2 June 2021. The latest transaction was disclosed on 3 April 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations19 total
41,929 shares0Common StockSEC:0001215243-26-000004:0
27,778 shares0Common StockSEC:0001215243-25-000001:0
27,778 shares@ US$0.8063100.0% of flowCommon StockSEC:0001215243-24-000001:0
52,593 sharesCommon StockSEC:0001415889-23-016377:0
54,201 shares0Common StockSEC:0001415889-23-009216:0
83,054 shares0Class A Common StockSEC:0001140361-23-026971:0
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005634:0
Ideal exit: 5 Dec 2023 (T+270)
20,576 shares0Common StockSEC:0001215243-23-000001:0
12,788 shares0Common StockSEC:0001415889-22-008659:0
29,240 shares0Common StockSEC:0001215243-22-000001:0
6,049 shares0Class A Common StockSEC:0001140361-22-020582:0
721 shares0Class A Common StockSEC:0001209191-21-055888:0
721 shares0Class A Common StockSEC:0001209191-21-055888
3,000 sharesCommon StockSEC:0001179110-21-007131
3,000 sharesCommon StockSEC:0001179110-21-007131:0
5,555 shares0Common StockSEC:0001179110-21-007035
5,555 shares0Common StockSEC:0001179110-21-007035:0
4,592 shares0Common StockSEC:0001596771-21-000038:0
4,592 shares0Common StockSEC:0001596771-21-000038
19 of 19 declarations
About BUCKMAN PAUL
Paul Buckman is a Director at NeuroOne Medical Technologies Corp, Miromatrix Medical Inc., and Helius Medical Technologies, Inc. In this role, he brings his expertise in corporate governance and strategy. His diverse experience in the medical sector allows him to effectively contribute to the boards of these companies, ensuring their growth and regulatory compliance.
